| Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer |
25 |
| Re-education of macrophages as a therapeutic strategy in cancer |
22 |
| Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials |
21 |
| Gold nanoparticles-mediated photothermal therapy and immunotherapy |
20 |
| Future perspectives of therapeutic monoclonal antibodies |
14 |
| Enhancing tumor T cell infiltration to enable cancer immunotherapy |
14 |
| Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety |
14 |
| Dual role of macrophage in tumor immunity |
14 |
| Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action |
14 |
| CD73: an emerging checkpoint for cancer immunotherapy |
14 |
| Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma |
13 |
| Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison |
13 |
| Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab |
12 |
| INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study |
12 |
| Regulation of innate and adaptive antitumor immunity by IAP antagonists |
12 |
| Current state and future prospects of immunotherapy for glioma |
12 |
| Radiation therapy and immunotherapy: what is the optimal timing or sequencing? |
11 |
| Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis |
11 |
| Clinical significance of signs of autoimmune colitis in F-18-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients |
10 |
| Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA |
10 |
| Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution |
10 |
| Biologics for hidradenitis suppurativa: an update |
10 |
| Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages |
10 |
| Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis |
10 |
| Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review |
9 |
| Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab |
9 |
| PD-1/PD-L1 in disease |
9 |
| Etanercept for the treatment of rheumatoid arthritis |
9 |
| Fostamatinib for persistent/chronic adult immune thrombocytopenia |
9 |
| First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment |
8 |
| Plasmonic gold nanostar-mediated photothermal immunotherapy for brain tumor ablation and immunologic memory |
8 |
| Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series |
8 |
| Metabolic regulation of CAR T cell function by the hypoxic microenvironment in solid tumors |
8 |
| Vitamin D aggravates breast cancer by inducing immunosuppression in the tumor bearing mouse |
8 |
| Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity |
8 |
| Long-term effect of monophosphoryl lipid A adjuvanted specific immunotherapy in patients with grass pollen allergy |
7 |
| Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis |
7 |
| Abscopal effect in lung cancer: three case reports and a concise review |
7 |
| Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy |
7 |
| Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis |
7 |
| Rituximab in pemphigus |
7 |
| Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS >= 50%) metastatic NSCLC at US oncology practices |
6 |
| Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis |
6 |
| Comparative study of adjuvants for allergen-specific immunotherapy in a murine model |
6 |
| Immunometabolism: an overview and therapeutic prospects in autoimmune diseases |
6 |
| Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy |
6 |
| Biologics switch in psoriasis |
6 |
| An overview of cancer immunotherapeutic strategies |
5 |
| Nanoparticle-based CpG-oligonucleotide therapy for treating allergic asthma |
5 |
| State of the art in immunotherapy of neuroblastoma |
5 |
